We describe a new imaging method for detecting prostate cancer, whether localized or disseminated and metastatic to soft tissues and bone. The method relies on the use of imaging reporter genes under the control of the promoter of AEG-1 (MTDH), which is selectively active only in malignant cells. Through systemic, nanoparticle-based delivery of the imaging construct, lesions can be identified through bioluminescence imaging and single photon emission-computed tomography in the PC3-ML murine model of prostate cancer at high sensitivity. This approach is applicable for the detection of prostate cancer metastases, including bone lesions for which there is no current reliable agent for non-invasive clinical imaging. Further, the approach compares favorably to accepted and emerging clinical standards, including positron emission tomography with [ 18 F]fluorodeoxyglucose and [ 18 F]sodium fluoride. Our results offer a preclinical proof of concept that rationalizes clinical evaluation in patients with advanced prostate cancer.
INTRODUCTION
A transcription-based imaging, therapeutic or theranostic system can be considered for clinical translation if it meets certain criteria such as high tumor specificity, broad application and minimal toxicity (1, 2) . The first two criteria can be met through the choice of a strong and tumor-specific promoter. For example, cancer-specific gene therapy with the osteocalcin promoter, delivered through intra-lesional administration of an adenoviral vector, caused apoptosis in a subset of patients with prostate cancer (PCa) (2, 3) . We have shown that cancerspecific imaging could be accomplished in experimental models of human melanoma and breast cancer by systemic delivery of imaging reporters under the transcriptional control of the progression elevated gene-3 promoter (PEG-Prom) (1, 4) . Here we describe a nanoparticlebased, molecular-genetic imaging system employing the astrocyte elevated gene-1 promoter (AEG-Prom) (5) for detecting metastases due to PCa, including to bone, for which there is no reliable clinical imaging agent.
transiently transfected with the wild-type and mutated plasmid for the subsequent luciferase assay, as described above. PC3-ML and PC3-ML-Luc cells were expanded over three to five passages. Cells were harvested and diluted in sterile Dulbecco's PBS lacking Ca 2+ and Mg 2+ (Invitrogen Life Technologies). For intravenous injection, mice were administered 1 x 10 6 PC3-ML cells in 100 μL of sterile Dulbecco's PBS via the tail vein. To ensure hematogenous dissemination, including to the bone, the cells were injected into the left ventricle of the heart (27, 28) . For this intra-cardiac model mice were anesthetized with ketamine (100 mg/kg) and xylazine (20 mg/kg) and inoculated into Research.
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Author Manuscript Published OnlineFirst on August 21, 2014; DOI: 10.1158/0008-5472.CAN-14-0018 the left ventricle with 5 x 10 4 PC3-ML-Luc enriched or PC3-ML cells in a total volume of 100 μL of sterile Dulbecco's PBS using a 26 3/4 -gauge needle. To image the PC3-ML-Luc cells with BLI, mice were injected intraperitoneally (IP) with 100 μL of 25 mg/mL of D-luciferin solution (Caliper LifeSciences, Hopkinton, MA), and BLI was performed 20 min after the intra-cardiac injection to detect the distribution of cells. Mice were imaged weekly. Images were acquired on an IVIS Spectrum small animal imaging system (Caliper Life Sciences, Alameda, CA) and results were analyzed using Living Image software (Caliper Life Sciences). A group of agematched healthy NOG mice served as a negative control for the PCa metastasis model.
Enrichment of PC3-ML-Luc cells.
The PC3-ML-Luc cells were further selected for bone-homing tendency. Mice bearing PC3-ML-Luc tumors developed through the intra-cardiac injection method were monitored for tumor formation by BLI. After five weeks, following euthanasia the femur and tibia of the regions demonstrating clear signal were aseptically dissected. The tumor cells were established in culture by mincing the epiphysis and flushing the bone marrow with 1X PBS (Invitrogen Life Technologies) as described previously (26) . The subpopulations of cells selected using a Transwell migration chamber with an 8 μm pore size (BD Falcon, San Jose, California) were tested and confirmed for Luc expression as described previously (30) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 21, 2014; DOI: 10.1158/0008-5472.CAN-14-0018 formed according to the manufacturer's instructions. For systemic delivery 40 µg of DNA and 4.8 µL of 150 mM in vivo-jetPEI® was diluted in endotoxin-free 5% (wt/vol) glucose separately.
The glucose solutions of DNA and l-PEI polymer were then mixed together to give an N:P ratio (the number of nitrogen residues of vivo-jetPEI® per number of phosphate groups of DNA) of 6:1 in a total volume of 400 µL. The DNA-PEI polyplex was injected IV as two 200 µL injections with a 5 min interval.
Bioluminescence imaging. In vivo BLI was conducted at 24 and 48 h after the systemic delivery of reporter genes. Mice were imaged with the IVIS Spectrum. For each imaging session mice were injected IP with 150 mg/kg of D-luciferin, potassium salt under anesthesia using a 2.0% isoflurane/oxygen mixture. Ex vivo BLI was conducted within 10 min of necropsy. Living Image 2.5 and Living Image 3.1 software were used for image acquisition and analysis. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
SPECT-CT imaging and data analysis.
Author Manuscript Published OnlineFirst on August 21, 2014; DOI: 10.1158/0008-5472.CAN-14-0018 Statistical Analysis. For BLI error bars in graphical data represent mean ± standard deviation (SD). P-values < 0.05 were considered to be statistically significant.
RESULTS

Comparison of cancer specificity of AEG-Prom and PEG-Prom by bioluminescence imaging (BLI) in PCa.
To examine the cancer-specific activity of AEG-Prom we constructed two plasmids, pAEG-Luc, expressing firefly luciferase, and pAEG-HSV1tk, expressing the herpes simplex virus type I thymidine kinase (Supplemental Fig. S1 ). AEG-Prom drives the expression of the imaging reporter genes firefly luciferase (Luc) and HSV1-tk, which enable BLI and radionuclide basedtechniques, respectively. Given the high sensitivity and ease of BLI, our initial studies used this modality for proof of concept. The HSV1-tk reporter gene was used, as before (1), to provide a method that has a clear path to clinical translation. The PEG-Prom construct, namely, pPEG-Luc, was generated previously (1), and was used as a comparison for some of the current studies.
Using BLI we tested the cancer specificity of AEG-Prom and PEG-Prom in different PCa cell lines, Robust expression from AEG-Prom and PEG-Prom was observed only in the malignant cell lines, whereas promoter activity was negligible in the normal prostate epithelial cells (PrEC) ( Fig. 1A) .
To elucidate further the role of c-Myc in the activation of AEG-Prom, we engineered an AEG-Research.
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Prom containing mutations in the two E-box elements, to which the c-Myc transcription factor was hypothesized to bind in PCa cells, to produce pAEG-mEbox1&2-Luc, similar to the one reported in Lee et al. (5) (Fig. 1B) . The mutant pAEG construct, pAEG-mEbox1&2-Luc, consists of AGAGTG and AGATTG in lieu of the consensus CACGTG in the Ebox1 and 2 regions of the promoter, respectively. Those constructs were transiently transfected into PC3-ML cells, and the promoter activities were compared with those of the wild-type AEG-Prom construct, pAEG-Luc. As shown in Fig. 1B , the pAEG-mEbox1&2-Luc is still active in the PC3-ML cell line, although there was a three-fold reduction in the extent of activation of the AEG-Prom construct. Furthermore, we note that the AEG-Prom activity increases by six-fold as it goes from a no-c-myc state in the AR-CaP-E cells to a substantial c-myc state in the AR-CaP-M clone ( Fig. 1A) (Supplemental Fig. S2 shows c-Myc levels). These results indicate that AEG-Prom activity is regulated primarily, but not exclusively, by the c-Myc transcription factor in these cancer cells.
We then tested and compared the specificity of AEG-Prom and PEG-Prom in vivo in a relevant experimental model of PCa. To develop this model we used two human PCa sub-lines selected from initial metastases of the parental human PC3 cells that targeted the murine lumbar vertebrae, hence ML (metastasis lumbar). We used PC3-ML cells and the luciferase-tagged version of the PC3-ML cells, namely, PC3-ML-Luc (26-28), which were injected either intravenously (IV) or directly into the left ventricle of the heart to ensure widespread dissemination -including to bone. BLI confirmed the presence of widespread metastases to liver, kidney, lung and bone after IV injection of PC3-ML-Luc cells (Supplemental Fig. S3 ). We
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Author Manuscript Published OnlineFirst on August 21, 2014; DOI: 10.1158/0008-5472.CAN-14-0018 assumed a similar time course for the development of metastases from the PC3-ML cells that did not express Luc so that we could use them in conjunction with the AEG-Prom-driven system to identify metastatic lesions by BLI. Mice received an IV dose of pAEG-Luc-PEI and pPEG-Luc-PEI polyplexes ( Fig. 2 and Supplemental Fig. S4 ). Twenty-four and 48 h after plasmid DNA delivery, BLI revealed AEG-Prom-and PEG-Prom-driven gene expression above background only in the model demonstrating metastasis (Fig. 2B, D) and not in the healthy control group ( Fig.   2A, C) .
Histological analysis of the photon-emitting regions within lung for the animals treated with pAEG-Luc or pPEG-Luc showed the presence of tumor and the correlative Luc expression in the cancer models, but not in the controls ( Fig. 2E, F, I, J) . In the lungs Luc expression was detected by immunohistochemistry (IHC) from uniformly scattered tumor cells with some forming large, nodular aggregates. Lesions infiltrate capillaries, interstitium, septae and larger blood vessels ( Fig. 2F, J) . The kidneys also demonstrated multiple metastases. Tumor replaced all normal tissue except individual glomeruli (indicated by "G" in Fig. 2G, K) . Tumor cells in the liver formed multifocal nodules that in some cases demonstrated adjacent necrosis. Necrotic centers (indicated by "N" in Fig. 2H, L) correlated with a lack of Luc expression. We have also shown that expression of c-myc correlates with AEG-Prom-driven Luc expression within tumor ( Fig. 2E, F, G) . Similar expression of the c-myc or the Luc genes was not evident in the healthy, control mice.
BLI signal intensity was significantly higher in the PCa group compared to controls within lung at
both the 24 and 48 h time points (after administration of pAEG-Luc and pPEG-Luc) (P < 0.0001; Fig. 2M) . Moreover, at the 48 h time point we observed an approximately two-fold higher Luc gene expression from the AEG-Prom group as compared to the PEG-Prom group (Fig. 2M) . To compare the transfection efficiency between the lungs in pAEG-Luc and pPEG-Luc treated PCa-1-3 ( Fig. 2M and Supplemental Fig. S5) , we quantified the amount of plasmid DNA delivered to each of the lung tissues. We performed quantitative real-time PCR with a primer set designed to amplify a region of the Luc-encoding gene in the pAEG-Luc and pPEG-Luc plasmids (Supplemental Fig. S5 ). We used total DNA extracted from the lungs as a template. The difference in transfection efficiency in the PCa lungs between the pAEG-Luc and the pPEG-Luc group was not significant. That confirms that Luc expression from the pAEG-luc treated PCa models was due to the higher tumor-specific activity of AEG-Prom rather than higher transfection efficiency to malignant tissues. A possible reason for elevated expression using AEG-Prom in vivo includes that a human gene may demonstrate more productive interaction with the human proteins of the Ras-signaling pathway such as c-Myc (PEG-Prom is of rat origin and expression is not dependent on these signaling pathways) (4). Alternatively, AEG-Prom expression might be elevated further in vivo as a consequence of epithelial to mesenchymal transition (EMT). Further experimentation will be required to determine if that hypothesis is correct.
To enable reliable formation of metastasis to bone, a tissue prominently involved in human metastatic PCa, we injected PC3-ML-Luc and PC3-ML cells through an intra-cardiac route (Supplemental Fig. S3A) . Once timing for the development of metastases was determined for Research.
Author Manuscript Published OnlineFirst on August 21, 2014; DOI: 10.1158/0008-5472.CAN-14-0018 the luciferase-expressing cells, we then studied metastases due to PC3-ML cells using the pAEG-Luc-PEI polyplex. At 48 h after plasmid delivery we observed AEG-Prom-mediated expression of Luc from the PC3-ML models, as shown for PCa-4 and PCa-2 and not from controls ( Figs. 3 and   4 , respectively). For PCa-4, when imaged seven weeks after cell injection, BLI was able to detect cancer cells in the left tibia (Fig. 3B) , as confirmed by histological analysis (Fig. 3C) . The BLI signal intensity, from deep within the bone, was weak in vivo, likely due to attenuation by living tissues (32) .
Ex vivo BLI of PCa-2, when imaged five weeks after cell injection, showed the presence of tumor in the lungs, liver, adrenals and kidneys, as also confirmed by gross pathology, histological analysis and Luc IHC (Fig. 4C, D and Supplemental Fig. S6) . To study the transfection efficiencies of systemically delivered construct within lung and liver ( Fig. 4E and Supplemental   Figs. S6 and S7) , we quantified the amount of plasmid DNA delivered to each of these tissues.
We performed quantitative real-time PCR with a primer set designed to amplify a region of the Luc-encoding gene in the pAEG-Luc plasmid. We used total DNA extracted from the lung and liver as a template. The differences in transfection efficiency between areas of high tumor burden vs. those of low tumor burden within liver in same animal, as well as between areas of high tumor burden within liver vs. normal liver, were significant at P < 0.0005 and P = 0.0078, respectively. Lower transfection efficiency in diseased vs. normal liver was likely due to lower delivery of plasmid to the diseased tissue, as demonstrated previously for PEG-Prom and lung replete with metastases (1). PCR was also performed in tissues from control animals after pAEG-Luc delivery. Differences in transfection efficiency within lungs and liver between the Research.
Author Manuscript Published OnlineFirst on August 21, 2014; DOI: 10.1158/0008-5472.CAN-14-0018 control group and the PCa group were not significant. That confirms that higher visualized Luc expression from the PCa models is due to the tumor-specific activity of AEG-Prom rather than higher transfection efficiency to malignant tissues.
Radionuclide imaging of cancer via AEG-Prom. BLI is limited to pre-clinical studies due to the dependence of signal on tissue depth, the need for administration of exogenous D-luciferin substrate at relatively high concentration for light emission, rapid consumption of D-luciferin leading to unstable signal, and low anatomic resolution (1). Accordingly we cloned pAEG-HSV1tk (Supplemental Fig. S1B ), which can be detected by the radionuclide-based techniques of PET or single photon emission computed tomography (SPECT), upon administration of a suitably radiolabeled nucleoside analog (33) . We examined the SPECT-CT imaging capabilities Fig. 5 shows a representative example, PCa-3, for which we were able to detect the presence of multiple metastatic lesions with the pAEG-HSV1tk system. We then compared the sensitivity of the AEG-Prom imaging system to the current clinical PET-based methods for detecting soft tissue (FDG-PET) and bony (NaF-PET) metastatic lesions due to PCa. Fig. 5A, B show representative examples, PCa-3, and a healthy control, Ctrl-1, imaged with each method. Because NaF is a bone-seeking agent, there is substantial uptake within the normal Research.
Author Manuscript Published OnlineFirst on August 21, 2014; DOI: 10.1158/0008-5472.CAN-14-0018 skeleton (34) , which may obscure lesions within bone (Fig. 5A) . Moreover, on NaF bone scan skeletal metastases are seen indirectly, depending on the reaction of bone to the lesion, while the AEG-Prom polyplex images tumor directly. The NaF-PET/CT study for PCa-3 appears similar to that for Ctrl-1. NaF-PET/CT failed to identify the metastases within the tibia and axial skeleton. The same mouse also underwent FDG-PET/CT, which was only able to identify a lesion in the left scapula (L1, Fig. 5B ).
BLI performed ex vivo and gross pathology of lesions within the right humerus, dorsal thoracic wall, ribs, sternum and the heart confirmed that tumor was the source of signal seen on the living images ( Fig. 5C -E and Supplemental Fig. S8, respectively) . We were able to identify a 3 mm tumor nodule on the heart (L2, Supplemental Fig. S8B) , a 5 mm lesion in the dorsal thoracic wall adjacent to the mid-spine (L3, Fig. 5D ) and a 1 mm lesion in the ventral midline of the sternum (L4, Fig. 5D ). Furthermore, the macroscopic picture confirmed metastases in the bone marrow within the proximal tibia (L5, Fig. 5E, red dotted circles ). An ex vivo plain film image of the pelvis of PCa-3 did not delineate bone lesions clearly (Supplemental Fig. S8C ), suggesting advanced changes in skeletal morphology might be needed for detection with conventional imaging modalities.
DISCUSSION
Our goal was to develop a systemically deliverable construct for molecular-genetic imaging of metastatic lesions within both soft tissue and bone in a relevant model of PCa. Others have developed in vivo molecular-genetic imaging agents for PCa using adenoviral mediated, Research.
Author Manuscript Published OnlineFirst on August 21, 2014; DOI: 10.1158/0008-5472.CAN-14-0018 prostate-specific regulatory elements. Native androgen-dependent promoters/enhancers derived from prostate-specific antigen (PSA) (35) , probasin (36), human glandular kallikrein2 (37) and the prostate-specific membrane antigen (PSMA) (38) have been used to drive transgene expression, but in a tissue-restricted, rather than a tumor-specific manner (39) .
Additionally, promoters such as PSES (PSA promoter/enhancer) have been improved by incorporating the TSTA system, a two-step transcriptional amplification mechanism using the Gal4-VP16 fusion protein to enhance the transcriptional activity of weak PSES (40) .
In comparison to the above mentioned prostate-specific promoters, the tumor-specific promoters of PEG-3 and AEG-1 have certain features that might render them more specific and selective while at the same time instill them with greater utility, namely to use them in a variety of cancers beyond PCa. PEG-Prom and AEG-Prom: [1] maintain universal cancer specificity regardless of the tissue of origin; [2] do not require amplification to achieve high sensitivity;
and, [3] are systemically delivered using a non-viral delivery vehicle. We note that the expression levels of both the AEG-Prom and PEG-Prom increase in the mesenchymal clone of the ARCaP cell line compared with the epitheilial clone of the same cell line. (Fig. 1A) , indicating a possible level of involvement in EMT.
To recapitulate the clinical characteristics of PCa metastasis, we implemented a bone metastatic model of PCa, which occurs spontaneously after the IV injection of PCa cells without orthotopic injection directly to bone. In animals showing tibial lesions using BLI of PC3-ML-Luc cells, subsequent SPECT/CT was able to detect these lesions in all animals tested (Fig. 5B) . In Research.
Author Manuscript Published OnlineFirst on August 21, 2014; DOI: 10.1158/0008-5472.CAN-14-0018 perhaps the example closest to ours, Wu et al. previously utilized the PSES-TSTA bioluminescent vector to identify tibial bone marrow metastases that could not be detected by FDG-or NaF-PET/CT (38) . In addition to using a tissue-specific promoter, that study also differed from ours in that an orthotopic tibial PCa model was used, an adenoviral vector served as the delivery vehicle and TSTA amplification was employed to boost the promoter activity by several orders of magnitude as compared to the parental PSES vector (40) .
By using a biodegradable polymer, in vivo-jetPEI®, we tried to avoid certain problems that may arise when employing viral vectors, such as immune-mediated toxicity, inflammation and liver tropism (41) . We checked the ability of the non-viral delivery vehicle to provide widespread, systemic dissemination of plasmid by conducting quantitative PCR on sections of lung and liver and compared the transfection efficiency between controls and animals affected with PCa ( Fig.   4 ). Group differences in gene delivery between lung and liver were insignificant. This study also confirmed our earlier results that nanoparticle delivery is most efficient to wellvascularized tissues (1) . Liver tissue sections with a high tumor burden had significantly lower (P < 0.005) delivery of plasmid DNA, possibly due to the reduced vasculature of this tissue, which was also likely under high hydrostatic pressure and was adjacent to necrotic areas.
Although imaging was mediated through activation of AEG-Prom, delivery was in part mediated through the enhanced permeability and retention (EPR) effect, interaction of positively charged DNA-PEI polyplex with the cell membrane followed by endocystosis, release from endosomes and entry into the nucleus (42) .
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The methods used in this report are intended to enable rapid clinical translation. Accordingly, for systemic delivery we used a non-viral delivery vehicle, which has seen clinical use (l-PEI) (ClinicalTrials.gov #NCT01435720), and have employed an imaging reporter gene/probe pair (HSV1-tk/FIAU) that has previously been used in patients (33) . Nevertheless there are several hurdles that must be overcome, arguably the most significant of which is the delivery of the nanoparticles to the malignant tissue. Several excellent reviews on that topic have recently been published (43) (44) (45) , with recognized obstacles including tumor heterogeneity, elevated interstitial fluid pressure, shifting properties of the microenvironment and the difficulty of translating optimized conditions for animal systems to the clinic (46, 47) . Strategies for enhancing tumor delivery include surface functionalization by affinity agents, particularly agonists that promote internalization (48) , and surface coating with polyethylene glycol to increase circulation times. Other aspects requiring optimization include the reporter gene/probe pair, assuring that the gene is non-immunogenic and that the probe has pharmacokinetics suitable for detection using widely available imaging modalities (49) .
AEG-Prom enables a sensitive method for molecular-genetic imaging of PCa in vivo. From mutational analysis of AEG-Prom we have shown that its activation relies significantly on c-Myc binding to the two E-box elements as discussed above. As Ras-mediated c-Myc signal transduction is a pathway present in nearly all malignancies yet is absent in normal tissue (50), we anticipate that AEG-Prom will enable imaging of a wide variety of cancers directly and specifically.
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